| Autor: |
Voigt EA; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA. emily.voigt@aahi.org., Gerhardt A; Product Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Hanson D; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Jennewein MF; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Battisti P; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Reed S; Product Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Singh J; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Mohamath R; Formulation Sciences, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Bakken J; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Beaver S; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Press C; Product Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA., Soon-Shiong P; ImmunityBio, Inc, Culver City, CA, 90232, USA., Paddon CJ; Amyris, Inc, Emeryville, CA, 94608, USA., Fox CB; Formulation Sciences, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.; Department of Global Health, University of Washington, Seattle, WA, 98195, USA., Casper C; RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.; Product Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.; Formulation Sciences, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.; Department of Global Health, University of Washington, Seattle, WA, 98195, USA.; Department of Medicine, University of Washington, Seattle, WA, 98195, USA.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA. |
Full text from SpringerLink